Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Clinical trial NCT05101629 · COMPLETED
Trial details
- NCT number
- NCT05101629
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-11
- Primary completion
- 2025-06-30
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.